Antibiotics are often prescribed in the emergency department (ED) to patients presenting with a suspected infection before any definitive diagnosis can be made \[[@CR1]\]. However, increasing antibiotic resistance and detrimental effects on the microbiota require their use to be limited to those with a high likelihood of bacterial infection or the potential for further clinical deterioration. Conversely, withheld or delayed treatment in higher severity patients may lead to increased morbidity and mortality rates \[[@CR2]\]. Thus, an accurate assessment of antibiotic requirement and speed of administration is crucial.

Current tools to aid clinical decision-making include the use of procalcitonin (PCT) and C-reactive protein (CRP). However, recent interventional evidence in the ED has shown few differences between conventional biomarker-guided therapy and standard practice \[[@CR1], [@CR3]\], despite protocol compliance, patient selection and cut-off concerns. This post hoc analysis of a patient subset (Malmö, Sweden) from our previous investigation \[[@CR4]\] compared the use of PCT, CRP and lactate to the novel biomarker mid-regional proadrenomedullin (MR-proADM) in guiding antibiotic administration during treatment within the ED.

Within this subset (*N* = 213), 26 (12.2%), patients were prescribed antibiotics \< 48 h prior to presentation, whilst 187 (87.8%) were administered antibiotics during ED assessment. Of these patients, 164 (77.0%) were treated with intravenous (i.v.) and 23 (10.8%) with oral antibiotics. The median time to initial administration was 93 \[28--160\] min, with 71 (43.8%) patients receiving therapy within 60 min. Univariate and multivariate logistic regression found that MR-proADM had the strongest association with the requirement for antibiotic administration during ED treatment (Table [1](#Tab1){ref-type="table"}). Interestingly, MR-proADM (Spearman *ρ* = − 0.31, *p* \< 0.001) and lactate (Spearman *ρ* = − 0.25, *p* = 0.002) were the only parameters to be significantly negatively correlated with the time to antibiotic administration, with significant differences found at optimised MR-proADM cut-offs for antibiotic administration (1.27 nmol/L: 139 \[76--211\] vs 43 \[26--135\] min; *p* \< 0.001) or pre-established \[[@CR4]\] cut-offs for mortality prediction (1.54 nmol/L: 124 \[33--199\] vs 42 \[26--122\] min; *p* = 0.002). Similar results were also found for MR-proADM within previously established PCT concentration ranges \[[@CR5]\] (Table [2](#Tab2){ref-type="table"}), with an absence of ICU admission or 28-day mortality in patients with low MR-proADM concentrations, despite lower antibiotic administration rates and a significantly longer time to administration.Table 1Univariate and Multivariate analyses found that MR-proADM had the strongest correlation with the requirement for antibiotic administration during ED treatmentBiomarkerPatient population (*N*)Antibiotic administration (*N*)*p* valueC indexUnivariate OR \[95% CI\]Multivariate OR \[95% CI\]MR-proADM213164\< 0.0010.763.1 \[1.9--4.9\]3.3 \[1.9--5.9\]PCT213164\< 0.0010.742.7 \[1.7--4.3\]2.7 \[1.7--4.5\]CRP207159\< 0.0010.681.8 \[1.3--2.5\]1.9 \[1.4--2.8\]Lactate2041580.0020.661.8 \[1.2--2.6\]1.6 \[1.1--2.5\]Age, cardiovascular, neurological, renal and malignancy comorbidities were used as adjusting variables within the multivariate regression analysis, as previously outlined \[[@CR4]\]. Univariate and multivariate odds ratios were expressed per 1 SD increment of the log-transformed value for each respective biomarker. *CI* confidence interval, *CRP* C-reactive protein, *DF* degrees of freedom, *MR-proADM* mid-regional proadrenomedullin, *N* number, *OR* odds ratio, *PCT* procalcitoninTable 2Low MR-proADM concentrations resulted in an absence of ICU admission or 28-day mortality, despite lower antibiotic administration rates and a significantly longer time to administration, irrespective of corresponding PCT concentrationPatient subgroupsMR-proADM concentration\< 1.27 (nmol/L)≥ 1.27 (nmol/L)Subgroup 1: PCT concentration: \< 0.25 μg/L (*N* = 106) Patients (*N*)6541 Antibiotic administration (*N*, %)35 (53.8%)34 (82.9%) Time to antibiotic administration (min) (median, Q1-Q3)127 \[45.0--220\]42 \[25.8--116\] Composite of 28-day mortality and ICU admission (*N*, %)0 (0.0%)7 (17.1%)Subgroup 2: PCT concentration: ≥ 0.25 and \< 0.50 μg/L (*N* = 24) Patients (*N*)816 Antibiotic administration (*N*, %)7 (87.5%)15 (93.8%) Time to antibiotic administration (min) (median, Q1--Q3)165 \[88--305\]50 \[19.3--186\] Composite of 28-day mortality and ICU admission (*N*, %)0 (0.0%)1 (6.3%)Subgroup 3: PCT concentration: ≥ 0.50 μg/L (*N* = 83) Patients (*N*)2162 Antibiotic administration (*N*, %)15 (71.4%)59 (95.2%) Time to antibiotic administration (min) (median, Q1--Q3)131 \[92.8--166\]45 \[26--136.5\] Composite of 28-day mortality and ICU admission (*N*, %)0 (0.0%)15 (24.2%)*MR-proADM* mid-regional proadrenomedullin, *N* number, *PCT* procalcitonin, *Q* quartile

Results suggest that delayed antibiotic administration in patients with low MR-proADM concentrations may result in few adverse effects, potentially allowing for a more detailed clinical assessment prior to any subsequent initiation. Further studies in larger patient populations are required to confirm these initial findings.
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